Research programme: Nanobodies - Ablynx/Novartis

Drug Profile

Research programme: Nanobodies - Ablynx/Novartis

Latest Information Update: 13 Jul 2010

Price : $50

At a glance

  • Originator Ablynx
  • Developer Ablynx; Novartis
  • Class Single-domain antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation

Most Recent Events

  • 13 Jul 2010 Preclinical development is ongoing in Belgium
  • 05 Feb 2009 Ablynx and Novartis extend their alliance for a further year
  • 19 Feb 2008 Ablynx receives milestone payment from Novartis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top